Company intelligence / Profile preview
Telsar Pharma, Inc.
Bridgewater, New Jersey, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Telsar Pharma conducted a Phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ASP3291 in patients with active ulcerative colitis. The drug development was discontinued after this phase[2][7].
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecules (melanocortin receptor agonists)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Astellas Pharma Inc.Drais Pharmaceuticals, Inc.
Beyond the preview
Go deeper on Telsar Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telsar Pharma, Inc..